-Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19
-BHV-1200, a COVID-19 targeting MATE compound, recently completed in vitro testing that demonstrated activity against SARS-CoV-2 wild-type as well as mutants associated with reduced susceptibility to therapeutic monoclonal antibodies and emerging strains including the "English" and "South African" variants
-Based upon the in vitro profile against SARS-CoV-2 wild-type and variants, Biohaven will advance BHV-1200 into the clinic
PR Newswire
NEW HAVEN, Conn., Feb. 22, 2021